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To the Editor
The manuscript by Flodmark et al. [1] recently
published in the open-access journal Biologics in
Therapy describes a single-center experience in
Sweden of a switch from an originator biologic
to a biosimilar human growth hormone (rhGH)
using a dialogue teamwork approach [1].
Unfortunately, the authors fail to mention
several limitations to their study which call
into question their conclusions.
To evaluate the effect on growth of switching
from originator to biosimilar rhGH, Flodmark
et al. [2] applied a modeling approach
previously developed based on limited Phase 3
clinical trial data. However, there are several
questions regarding the suitability of this
modeling approach and the methods used to
compare the effect of originator and biosimilar
rhGH on growth. First, it is unclear from either
the current or the previously published
manuscript whether the applied model has
been suitably validated using an appropriate
study population, with adequate sample sizes
and suitable treatment duration. In this regard,
the analysis described by the authors in their
current report appears to be one of prediction
model assessment, rather than treatment
comparison. Second, given the heterogeneity
in the diagnoses and pubertal status of the
population treated with growth hormone, it is
not clear whether the same prediction model
would be appropriate for the different patient or
diagnostic groups included in the current
analysis (see, e.g., Ranke et al. [3]. Third,
treatment history is not addressed by the
applied model, an important issue given that
prior treatment duration and history would be
expected to affect growth performance. Fourth,
the model employed by the authors [2] was
derived from a small number of patients treated
with originator rhGH for only 9 months,
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whereas Flodmark et al. use the same model to
make predictions over a 3-year period; the
validity of this extrapolation has not been
justified. It is also unclear how repeated
measures for each individual patient were
addressed, given that these affect the reporting
of coefficient of determination (R2) and
standard deviation (SD) and can lead to
spurious results. Finally, the reported age
range of subjects (1–15 years) included in the
manuscript by Flodmark et al. suggests that
some subjects may have been at the tail end of
their growth trajectory prior to switching rhGH
products and had limited anticipated growth
following the switch.
The manuscript by Flodmark et al. states that
there were no reports of serious or unexpected
adverse drug reactions (ADRs) following the
switch to biosimilar rhGH. It is not clear from
the report how the distinction between
unexpected and expected ADRs was
operationalized. However, they also state that
19 ADRs (18 pain at injection site and 1 pitting
edema) were reported in 18 patients. A
discussion about this rate is wanting. Is the
switch exposing patients to a higher rate of
ADRs than they would have experienced
without the switch? Is the rate comparable to
or higher than the rate normally observed when
patients start a new treatment? To illustrate the
relevance of the latter question, a comparison
was made between the rate of ADRs in this
report with the rate observed in a prospective
clinical study that compared ease of use and
preference for a new disposable rhGH injection
pen relative to previous experience with the
currently available reusable pen in standard
practice. Hey-Hadavi et al. [4] reported 8 device-
related ADRs in 7 out of 137 subjects (5.1%;
injection-site hematoma in 3 and injection-site
pain in 5) compared to 18 cases in 98 patients
(18.4%) reported by Flodmark et al. Although,
one should be very cautious about drawing
conclusions from a side by side comparison of
ADRs between two studies, where the methods
to collect and register the ADRs as well as the
definitions of ADRs may have differed, there are
no reasons to expect that study of Hey-Hadavi
would systematically underestimate the
number of injection-site-related ADRs
compared to Flodmark study.
Flodmark et al. suggest that the switch to
biosimilar rhGH was acceptable to patients
since 98 of the 102 offered the switch agreed.
Later in the paper, the authors comment that
the switch of device types is not necessary
without a consequence in that ‘‘switching to a
different rhGH product also involves the use of
a new injection device. Consequently, patients
must learn, and get used to, a different injection
technique’’. Previous studies of ease of use of
injection devices [4] suggest that not all devices
are similar in ease of use. In addition, as pointed
out by Grimberg et al. [5], both clinic costs and
non-compliance risks associated with switching
are not inconsequential. Flodmark et al.
included neither in their assessment of
outcome.
This oversight is complicated by a failure of
the authors to address the cost of switching
when calculating the economic benefit of the
switch incurred due to differences in product
cost. One would expect that all costs and
benefits be considered in a rigorous economic
analysis. Finally, the authors report that
patients were given a choice of switching to
biosimilar rhGH or paying for the difference in
cost between their own product and the
biosimilar. Since the originator biologic was
reimbursed by the government it is not clear on
what grounds the clinic could have charged the
patients and indeed four patients were allowed
to continue without contributing to the cost of
therapy.
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These limitations, together with a lack of a
cautionary note on the danger of over-
interpretation of the result from this non-
interventional study, raise questions regarding
the validity of the study and its conclusions.
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